RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Redhill Biopharma Ltd.

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
Joint U.S. Commercialization of RedHill's Talicia® Commences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.